semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Glomerulonephritis Lupus Nephritis Systemic Lupus Erythematosus Patients must be 18 years of age or older and able to provide informed consent. Patients must have at least 4 for SLE as defined by the American Rheumatism Association (ARA). Active glomerulonephritis with: Renal biopsy within 1 year with class III or class IV active lupus nephritis, AND; Abnormal urine analysis: Greater than 10 RBC/hpf and cellular (RBC, WBC or mixed) casts, OR; Greater than 10 RBC/hpf and proteinuria greater than 2 g/day, OR; Proteinuria greater than 3.5 g/day. No patients with severe proliferative lupus nephritis: a. very active renal histology with crescents or necrosis in more than 25% of glomeruli; or b. rapidly progressive glomerulonephritis (doubling of serum creatinine in less than or equal to 3 months); or c. severe impairment of renal function Cr greater than 2.5 mg/dL or GFR less than 50 mL/min measured by inulin clearance. Patient has not had previous immunosuppressive therapy: Patients must not be receiving azathioprine, cyclosporine, methotrexate. Patients receiving these drugs will be eligible only if these drugs are discontinued and after a waiting period of greater than or equal to 4 weeks; Patients must not be receiving cyclophosphamide: Greater than 3 pulses (maximum 1 g/m(2)/pulse) within the last 12 months or since last renal biopsy showing active disease; OR greater than 6 pulses ever. Patients must not have had pulse therapy with glucocorticoids or any experimental therapy during the 4 weeks before study entry. Patients who need at study entry oral corticosteroids in dosages greater than 0.5 mg/kg/day of predisone to control extrarenal disease are not eligible. Patients with active or chronic infection are not eligible. Patients who are pregnant, breast-feeding or using inadequate birth control are not eligible. Patients who have poorly controlled diabetes mellitus or with evidence of end-organ damage are not eligible. No history of cerebrovascular accident, seizures within the last 5 years or chronic neurologic disease. No history of malignancy other than squamous cell and/or basal carcinoma of the skin. No confounding medical illness that in the judgment of investigators would pose added risk for study participants such as: Unstable coronary artery disease, cardiomyopathy or dysrhythmia requiring therapy; Pulmonary disease (PFTs less 70% of predicted value or DLCO less than 60%), or; Hematologic disease (Hb less than 8 mg/dL, platelets less than 100,000 micro liters or WBC less than 2,500/micro liters
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Histologically confirmed stage I, II, or III primary breast cancer undergoing breast surgery Invasive disease (e.g., lobular or ductal) No bilateral disease No distant metastases Premenopausal Regular menses (no amenorrhea of more than 90 days) without hormone replacement Documented last menstrual period Hormone receptor status Not specified Age Premenopausal Sex
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Healthy Deficiency Disease Ages 18-40. Men and women. BMI 30-34.9 kg/m2  Major medical or psychiatric diagnoses active within the past 3 years. Endocrine diseases like, thyroid disease, DM, pituitary, ovarian/testicular and adrenal problem Acute infections Irregular menstrual cycles (greater than 7 day menses, intervals greater than 35 or less than 21 days) A weight change of greater than 2% within the past 2 months. Use of prescription medications or other drugs/supplements including acetaminophen or alcohol that would, in the judgement of study investigators, interfere with study objectives Major (greater than 3 hours/week) athletic/physical exercise activities. Eating patterns or dietary preferences which would hinder compliance with study diets Tran meridian travel within 2 weeks preceding study periods Inability to comply with the study protocol Pregnancy Anemia. Hemoglobin less than 11.5 for women and less than 12.7 for men
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  HIV Infections HIV positive to 24 weeks pregnant Willing to take the planned antibiotic treatment Planning to deliver at 1 of the study sites Willing to come back for follow-up visits for 1 year after the baby is born  Have taken antibiotics, except for syphilis or gonorrhea, within the last 2 weeks Are allergic to penicillin, ampicillin, erythromycin, or metronidazole Have major illnesses, such as diabetes, severe kidney or heart disease, or active tuberculosis, which might affect the pregnancy Are having major problems with the pregnancy, such as placenta previa, ruptured membranes, or multiple pregnancy Have a central nervous system disease, such as seizures Are taking anticoagulant drugs
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Breast Neoplasms Metastases, Neoplasm Patients will be eligible for this trial if Female, non-pregnant, non-lactating, and, if of child-bearing potential, have a negative serum pregnancy test, and use approved contraception Sixteen years of age or older Histologically or cytologically confirmed breast cancer (stage III or IV) with evidence of inoperable local recurrence or metastasis, with measurable disease If patient has received taxane therapy as an adjuvant he/she has not relapsed within one year of completing adjuvant taxane No other malignancy present within the past 5 years, except non-melanoma skin cancer, cervical intraepithelial neoplasia or in-situ cervical cancer Suitable candidate for paclitaxel therapy Hematology levels at baseline of: absolute neutrophil count of at least 1500 cells/mm3; platelet count of at least 100,000 cells/mm3; hemoglobin of at least 9 g/dL Chemistry levels at baseline of: AST and ALT of less than or equal to 2.5 x the upper limit of normal, if no evidence of liver metastasis; total bilirubin of less than or equal to 1.5 mg/dL; creatinine of less than or equal to 2 mg/dL; alkaline phosphatase of less than or equal to 5 x the upper limit of normal, unless there is bone metastasis but not liver metastasis Expected survival of at least 12 weeks
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Cystic Fibrosis Eligible subjects will be randomized to two aerosolized doses of either tgAAVCF or placebo 30 days apart. Subjects will undergo pulmonary function testing every two weeks during the active portion of the study (three months) and will be followed for safety for a total of seven months
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Thyroid Diseases Age greater than or equal to 18 years, male or female. History of total or near total thyroidectomy or hypothyroidism on replacement therapy. For non-thyroidectomized patients, at least three-year history of replacement therapy (at least 1.2 mcg/Kg LT4/body weight), and less than 5% uptake at 24H on (123)I thyroid scan while on replacement therapy. Written informed consent  BMI less than or equal to 20 or greater than or equal to 30 kg/m(2). Metastatic thyroid cancer or history of thyroid cancer with high risk of recurrence requiring suppressive thyroid hormone therapy (Singer 1996). Significant thyroid residual greater than 1 mL as measured by ultrasound (limited to thyroidectomized patients) or greater than 5 percent uptake at 24H on (123)I thyroid scan while on replacement therapy (limited to hypothyroid patients not undergone total thyroidectomy). History or symptoms compatible with cardiovascular disease, including paroxysmal supraventricular tachycardia, atrial fibrillation, syncopal episodes or use of prescription medications for heart conditions, including antihypertensives. Allergy to lidocaine, isoproterenol, TRH, levothyroxine, liothyronine, Tylenol #3, oxycodone, nitroglycerin. Pregnancy or unwillingness to use non-hormonal contraception during the study. Breastfeeding Use of hormonal contraceptives or estrogen replacement therapy. Use of tobacco (smoking, chewing) for the two weeks preceding the hospital admissions (metabolic testing) Diabetes mellitus, either type I or II. Hypercholesterolemia (serum levels greater than or equal to 240 mg/dL), hypertriglyceridemia (plasma levels greater than or equal to 220 mg/dL) and/or use of antilipemic therapy. Liver disease or ALT serum level greater than two fold the upper laboratory reference limit. Renal insufficiency or estimated creatinine clearance less than or equal to 50 mL/min. Use of medications/supplements/alternative therapies known to alter thyroid function. Current history or symptoms compatible with psychosis including major depression (including history of hospitalization for depression, history of attempted suicide, history of suicidal ideation). Use of antipsychotic medications History of drug or alcohol abuse within the last 5 years; current use of drugs or alcohol (CAGE greater than 3). Keloid formation (relative to skeletal muscle and subcutaneous adipose tissue biopsies). Current or previous clinically significant (requiring medical/surgical intervention) extrathyroidal manifestations of autoimmune thyroid disease (dermopathy, ophthalmopathy, arthropathy)
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-17.0,  Osteopenia Not sexually active and agree to remain sexually inactive throughout the course of the study First menstrual period at least one year ago No menstrual period in the last 6 months  Undiagnosed abnormal genital bleeding Known or suspected pregnancy Medical history of any disorder that contraindicates the use of oral contraceptives
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 14.0-999.0,  Syncope, Vasovagal, Neurally-Mediated Syncope as a cause of loss of consciousness according to European Society of Cardiology > 2 lifetime syncopal spells preceding enrollment > or = to -2 points on the Syncope Symptom Score for Structurally Normal Hearts Age > 18 years with informed consent, or age > 14 years with consent and informed parental consent  Other causes of syncope, such as ventricular tachycardia, complete heart block, postural (orthostatic) hypotension or hypersensitive carotid sinus syndrome An inability to give informed consent Important valvular, coronary, myocardial or conduction abnormality or significant arrhythmia Hypertrophic cardiomyopathy A known intolerance to fludrocortisone Another clinical need for fludrocortisone that cannot be met with other drugs A permanent pacemaker A seizure disorder A major chronic non cardiovascular disease Hypertension (blood pressure ≥ 130/85 on 2 occasions) or heart failure
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Urinary Tract Infection Parturients planned for vaginal delivery  Parturients receiving antibiotic treatment during delivery or in the week before
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 5.0-18.0,  Anemia, Sickle Cell Active patient (presently receiving medical care for SCA) at the St. Jude Comprehensive Sickle Cell Center (SJCSCC) or an affiliate or alliance of St Jude. Patient must not be in the high risk category as defined by the High risk is defined as follows or more admissions and/or emergency department visits for pain within the past 12 months, or or more episodes of acute chest syndrome within the past 24 months, or A combination of pain and ACS events > 3 within the past 12 months 18 years of age Diagnosis of Hb SS or HB0Thal Weight >15 kg <50th percentile for height/age or weight/age or weight/ height, or <90% ideal body weight, or <90% of BMI for age/ gender Is willing to sign informed consent  Patients receiving hydroxyurea or any other anti-sickling agent, chronic transfusion, or nutrition supplements.A nutrition supplement is any high calorie or high protein food additive or oral supplement being used for the purpose of weight gain History of poor compliance (Missing two or more clinic appointments in the past year) Renal or liver dysfunction Renal dysfunction as defined by serum creatinine >1.5 times normal for age based on testing lab Hepatic dysfunction as defined by alanine aminotransferase (ALT) >2 times the upper limit of normal for age based on testing lab Breastfeeding Pregnancy.Females of childbearing potential must have negative serum or urine pregnancy test (record date of test) Patients enrolled on previous glutamine protocol (SCDGLU) Patients who are considered high risk
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.333-0.5,  Enteric Infections 6 months of age (stratified by HIV status) Infant able to take oral preparations Consent of parent/guardian HIV status obtained from mother and child  Documented micronutrient supplementation other than vitamin A in the preceding month Less than 60% of mean weight for age by NCHS guidelines (micronutrient intervention obligatory according to WHO guidelines for management of severely malnourished children) Persistent diarrhea (>=7 days) at the time of study enrollment Exclusive breastfeeding Infants in whom a second confirmatory HIV test cannot be obtained (when required) Co-enrollment of the infant in other clinical intervention trials e.g. antibiotic or vaccine trials
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Child Development Disorders Pregnancy Subclinical Hypothyroidism Pregnant female Normal TSH in second trimester Singleton pregnancy Term infant weighing 2500g or more No congenital abnormalities noted on birth record Delivery in Maine at 36 weeks or later  TSH levels outside normal range in second trimester Pre-existing hypothyroidism, treated More than one fetus Premature and/or low birth weight infant Congenital abnormalities noted on birth record
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Thyroid Neoplasms histological diagnosis of differentiated thyroid carcinoma total or near total thyroidectomy informed consent  no informed consent
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Thyroid Diseases All patients with benign thyroid disease  Unable to complete questionnaire: must be able to read and write Danish
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Hyperthyroidism Subclinical hyperthyroidism [TSH ≤ 0.1 mU/L, fT4 and T3 within the normal range of the own laboratory (determined 2 times in own laboratory) with an interval of at least 2 months] Endogenous cause of subclinical hyperthyroidism limited to autonomous adenoma or multinodular goiter (diagnosis made by the attending physician, based on palpation and the result of a thyroid scintigram) Informed consent  Medication with anti-thyroid drugs in the last 3 months (also not allowed during follow-up); thyroid hormone in the last 3 months (allowed during follow-up, but TSH levels should be kept between 0.1 mU/L and the upper limit of normal in the own laboratory); and oral glucocorticoids in the last 3 months (allowed during follow-up when absolutely necessary, but patients in whom glucocorticoids are started cannot be evaluated with respect to changes in bone mineral density [BMD]) Radioiodine therapy in the past Iodine-induced subclinical hyperthyroidism Pituitary or hypothalamic insufficiency Pregnancy Age <= 40 years Severe non-thyroidal illness Drug abuse Unstable angina pectoris, (history of) atrial fibrillation, (history of) congestive heart failure (History of) osteoporotic fracture(s)